Jun 02, 2022
Atossa Therapeutics Appoints Biotech Industry Communications Veteran Charles Butler as Vice President, Investor Relations and Public Relations
May 18, 2022
Atossa Therapeutics to Present at the H.C. Wainwright Global Hybrid Investment Conference
May 09, 2022
Atossa Therapeutics Announces First Quarter 2022 Financial Results and Provides Corporate Update
Apr 27, 2022
Atossa Therapeutics to Present at the Q2 Investor Summit Conference
Apr 20, 2022
Atossa Therapeutics Announces Completion of Part B of Clinical Study of AT-H201
Mar 23, 2022
Atossa Therapeutics to Present at the Maxim Group 2022 Virtual Growth Conference
Mar 08, 2022
Atossa Therapeutics Announces Issuance of Key U.S. Patent Covering Endoxifen
Feb 28, 2022
Atossa Therapeutics Announces Year-End 2021 Financial Results and Provides Corporate Update
Jan 27, 2022
Atossa Therapeutics President and CEO Dr. Steven C. Quay Issues Annual Letter to Stockholders Highlighting Key Recent Accomplishments and Strategy for 2022
Jan 18, 2022
Atossa Therapeutics Announces Advancement to Part B of Clinical Study of AT-H201
1
2
3
4
5
6
<<
<
>
>>
Privacy
